Mead Johnson Nutrition (MJN) and SanCor Enter Joint Ventor to Help Childern
Tweet
Share
E-mailGet Alerts MJN Hot Sheet
Join SI Premium – FREE
Mead Johnson Nutrition (NYSE: MJN) and SanCor Cooperativas Unidas Ltda. of Argentina today announced an undertaking in principle to form a joint venture that will bring leading and innovative nutritional products to infants and children in Argentina and the other Southern Cone markets.
The new joint venture – which would be owned 80% by Mead Johnson and 20% by SanCor – will develop dairy nutrition technology and provide science-based infant formulas and growing-up milks for babies and children. Working as an independent entity, it will develop and market products exclusively under the “SanCor Bebe” brand.
As a result of this alliance – as well as the combined marketplace experiences, insights and scientific research of the two companies – parents of babies and health care professionals can count on the continued availability and development of high quality, innovative pediatric nutrition products.
The new joint venture – which would be owned 80% by Mead Johnson and 20% by SanCor – will develop dairy nutrition technology and provide science-based infant formulas and growing-up milks for babies and children. Working as an independent entity, it will develop and market products exclusively under the “SanCor Bebe” brand.
As a result of this alliance – as well as the combined marketplace experiences, insights and scientific research of the two companies – parents of babies and health care professionals can count on the continued availability and development of high quality, innovative pediatric nutrition products.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Z Squared outlines AI power strategy and Paradox Data acquisition
- Cable One names Heather McCallion as chief operating officer
- VICI Properties closes $1.75B senior unsecured notes offering
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
